TKIs are used in first-line for chronic and acute myeloid leukemia (CML and AML) with BCR/ABL overexpression as well as for gastrointestinal stromal tumors (GIST) with c-KIT mutations (Bennasroune et al., 2004). Here, BCR is linked to acute myeloid leukemia.